News | December 28, 2011

Good Samaritan Hospital Investigates Drug-Eluting Balloons to Treat Peripheral Arterial Disease

December 28, 2011 – Good Samaritan Hospital in Los Angeles is participating in the Levant 2 clinical trial to investigate a potential new treatment option for people with peripheral artery disease (PAD). The clinical trial will help doctors determine whether a drug-coated angioplasty balloon will be more successful in keeping narrowed arteries open for longer compared to treatment with a non-coated standard angioplasty balloon.

An estimated 8 million Americans have peripheral artery disease, including the 12 to 20 percent of individuals older than age 60, according to the Centers for Disease Control. PAD is a disease in which plaque builds up in the arteries that carry blood to the head, organs and limbs. Plaque is made up of fat, cholesterol, calcium, fibrous tissue and other substances in the blood. When plaque builds up in the body's arteries, the condition is called atherosclerosis. Over time, plaque can harden and narrow the arteries, which eventually limits the flow of oxygen-rich blood to the organs and other parts of body.

PAD usually affects the arteries in the legs, but it can also affect arteries that carry blood from the heart to the head, arms, kidneys, and stomach. Many people who have PAD do not have any signs or symptoms. Others may experience difficulty when walking or climbing stairs. Physical exertion can cause pain, numbness, aching or heaviness in the leg muscles. Other symptoms may include cramping in the affected leg(s), in the buttocks, thighs, calves and feet.

Other clinical signs of PAD include:

  • Weak or absent pulses in the legs or feet
  • Sores or wounds on the toes, feet, or legs that heal slowly, poorly, or not at all
  • A pale or bluish color to the skin
  • Gangrene of the toes or feet
  • A lower temperature in one leg compared to the other leg
  • Poor nail growth on the toes and decreased hair growth on the legs
  • Erectile dysfunction, especially among men who have diabetes

Treatment for PAD focuses on reducing symptoms, preventing further progression of the disease and in most cases, lifestyle changes, exercise and claudication medications that can help slow the progression or even reverse the symptoms of PAD.

"Restenosis or renarrowing of arteries in the legs has been the 'Achilles Heel' of peripheral vascular interventions despite recent technological advances in angioplasty balloons, vascular stents and atherectomy devices," said Guy Mayeda, M.D., an interventional cardiologist at Good Samaritan Hospital. "If the paclitaxal-coated balloon under investigation in the Levant 2 trial demonstrates an ability to significantly reduce arterial renarrowing, it could establish a very significant change in the treatment of peripheral artery disease for potentially millions of patients."

The Levant 2 trial involves utilization of a new drug-coated balloon in the treatment of narrowed arteries in the legs. Patients considered for enrollment in the clinical trial are screened using an ultrasound test to assess the degree of narrowing and blood flow to the legs. 

For more information: www.Levant2.com, www.goodsam.org

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Overlay Init